Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).

@article{Stier2003AldosteroneAA,
  title={Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).},
  author={Charles T. Stier and Seth J. Koenig and D Y Lee and Mohit K. Chawla and William H. Frishman},
  journal={Heart disease},
  year={2003},
  volume={5 2},
  pages={
          102-18
        }
}
Aldosterone has long been known to mediate water and electrolyte balance by acting on mineralocorticoid receptors in the kidneys. However, recent studies have demonstrated the presence of these receptors in nonclassical locations, including the brain, blood vessels, and the heart. This finding suggests that aldosterone may play a larger role than once appreciated in normal physiologic function and cardiovascular disease. Some of the adverse cardiovascular effects that have been described… 
Aldosterone and aldosterone antagonism in systemic hypertension
TLDR
Eplerenone, more specific for the mineralocorticoid receptor, appears to provide all the beneficial effects of spironolactone in hypertensive patients, with the potential to modify many of the side effects related to nonspecific steroidreceptor blockade.
Aldosterone promotes endothelial dysfunction via prostacyclin independent of hypertension.
TLDR
Aldosterone has now been shown to promote cardiovascular inflammation, endothelial dysfunction, and fibrosis, and the demonstration of rapid aldosterone effects challenged the exclusive role of mineralocorticoid receptor-mediated genomic actions in ald testosterone signaling.
Aldosterone antagonists in the treatment of heart failure.
  • T. Marcy, Toni L. Ripley
  • Medicine, Biology
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2006
TLDR
Spironolactone and eplerenone are life-saving agents in patients with advanced heart failure and may benefit patients with mild heart failure.
Eplerenone in the treatment of chronic heart failure
  • H. Krum, D. Liew
  • Medicine, Biology
    Expert review of cardiovascular therapy
  • 2004
TLDR
The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study has provided firm support for the use of eplerenon (Inspra™, Pfizer) in heart failure following acute myocardial infarction in addition to neurohormonal blockade with angiotensin-converting enzyme inhibitors or angiotENSin II receptor blockers and β-blockers.
Aldosterone and volume management in hypertensive heart disease.
  • D. Sica
  • Medicine, Biology
    Seminars in nephrology
  • 2014
Aldosterone - the future challenge in cardiovascular disease?
TLDR
Focused experimental studies in humans and in animal models of hypertension have shown that aldosterone blockade improves a number of pathogenic abnormalities including vascular endothelial dysfunction and altered baroreflex function, and prevents the development of cardiac hypertrophy and renal histological damage.
Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
  • D. Sica
  • Medicine, Biology
    Methodist DeBakey cardiovascular journal
  • 2015
TLDR
Hyperkalemia should always be considered a possibility in patients receiving either spironolactone or eplerenone; therefore, anticipatory steps should be taken to minimize the likelihood of its occurrence if long-term therapy of these agents is being considered.
The risks and benefits of aldosterone antagonists
  • D. Sica
  • Medicine, Biology
    Current heart failure reports
  • 2005
TLDR
For most patients the risk of developing hyperkalemia should not dissuade the prudent clinician from use of spironolactone and eplerenone, but as enthusiasm grows for use of mineralocorticoid-blocking agents, the risks inherent to use of such drugs become more pertinent.
Review: Aldosterone — the future challenge in cardiovascular disease?
TLDR
Focused experimental studies in humans and in animal models of hypertension have shown that aldosterone blockade improves a number of pathogenic abnormalities including vascular endothelial dysfunction and altered baroreflex function, and prevents the development of cardiac hypertrophy and renal histological damage.
Aldosterone Receptor Antagonism in Heart Failure
TLDR
Nonclassic effects of increased collagen synthesis and myocardial fibrosis resulting in left ventricular hypertrophy are demonstrated and are attributed to mineralocorticoid receptor–mediated salt and fluid retention leading to increased afterload.
...
...

References

SHOWING 1-10 OF 118 REFERENCES
Eplerenone: a selective aldosterone receptor antagonist (SARA).
TLDR
In rodent models, eplerenone provides marked protection against vascular injury in the kidney and heart and is well tolerated in acute and chronic safety pharmacology studies, which will extend the understanding of selective aldosterone receptor antagonism in the treatment of chronic cardiovascular disease.
Aldosterone: cardiovascular assault.
TLDR
Eplerenone is a selective aldosterone blocker whose role in reducing morbidity and mortality rates in patients with cardiovascular disease is being investigated.
Aldosterone antagonists in the treatment of hypertension and target organ damage
TLDR
The evolution of selective aldosterone receptor antagonists will help to understand the role that mineralocorticoids play in the pathogenesis of hypertension, heart failure, and atherosclerosis.
Clinical implications of aldosterone blockade.
TLDR
Eplerenone is a selective aldosterone blocker that effectively lowers BP in both white and black patients with hypertension and provides meaningful further antihypertensive efficacy when added to patients whose hypertension is inadequately controlled by angiotensin-converting enzyme inhibitors or angiotENSin-receptor blockers.
Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
  • A. Sato, Y. Suzuki, T. Saruta
  • Medicine, Biology
    Hypertension research : official journal of the Japanese Society of Hypertension
  • 1999
TLDR
It is concluded that spironolactone may have beneficial effects on left ventricular hypertrophy in patients with essential hypertension who are receiving an angiotensin-converting enzyme inhibitor.
Aldosterone in congestive heart failure.
  • K. Weber
  • Biology, Medicine
    The New England journal of medicine
  • 2001
TLDR
A review article gives an in-depth update on the mechanisms of action of aldosterone and their implications for therapy and underscores the value of a Aldosterone-receptor antagonists, such as spironolactone, in the treatment of chronic heart failure.
Aldosterone and heart failure.
  • F. Zannad
  • Medicine, Biology
    European heart journal
  • 1995
TLDR
Experimental and clinical research should be further expanded to investigate the potential benefits of opposing the effects of aldosterone by use of specific antagonists or other potentially more potent pharmacological agents with favourable side-effect profiles.
Pathophysiological effects of aldosterone in cardiovascular tissues
...
...